Patents by Inventor Christian Klein

Christian Klein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bispecific T cell activating antigen binding molecules
    Patent number: 10781257
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: September 22, 2020
    Assignee: Roche Glyeart AG
    Inventors: Marina Bacac, Thomas Hofer, Ralf Hosse, Christiane Neumann, Christian Klein, Ekkehard Moessner, Pablo Umana, Tina Weinzierl
  • BISPECIFIC HER2 ANTIBODIES AND METHODS OF USE
    Publication number: 20200291131
    Abstract: The present invention relates to bispecific HER2 antibodies, novel HER2 antibody variants, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: January 16, 2020
    Publication date: September 17, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Rebecca Croasdale-Wood, Lydia Jasmin Hanisch, Guy Georges, Thomas Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Claudio Sustmann, Pablo Umana
  • MONOCLONAL ANTIBODIES AGAINST BCMA
    Publication number: 20200283545
    Abstract: The invention relates to new antibodies against BCMA, their manufacture and use.
    Type: Application
    Filed: March 17, 2020
    Publication date: September 10, 2020
    Inventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Marina Bacac, Camille Delon, Lydia Jasmin Hanisch, Anne Freimoser-Grundschober, Christian Klein, Ekkehard Moessner, Samuel Moser, Pablo Umana, Tina Weinzierl
  • Bispecific T cell activating antigen binding molecules
    Patent number: 10766967
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: September 8, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marina Bacac, Tanja Fauti, Sabine Imhof-Jung, Christian Klein, Stefan Klostermann, Ekkehard Moessner, Michael Molhoj, Christiane Neumann, Joerg Thomas Regula, Wolfgang Schaefer, Pablo Umana
  • Gesture language for a device with multiple touch surfaces
    Patent number: 10768804
    Abstract: A gesture language for a device with multiple touch surfaces is described. Generally, a series of new touch input models is described that includes touch input interactions on two disjoint touch-sensitive surfaces. For example, a mobile device can include a primary display on a “front” side of the device, and a secondary display or touch-sensitive surface on the “back” side of the device, such as a surface that is opposite the primary display. Accordingly, the gesture language can include a series of “back touch” interactions with the touch-sensitive surface on the backside of the device. Example interactions include direct and indirect touch input on the back side, as well as simultaneous touch input on both sides of the device.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: September 8, 2020
    Assignee: Microsoft Technology Licensing, LLC
    Inventors: Christian Klein, Gregg Robert Wygonik, Ricardo A. Espinoza Reyes, Raymond Quan, Sophors Khut
  • ANTI-LAG3 ANTIBODIES
    Publication number: 20200277372
    Abstract: The present invention relates to anti-LAG3 antibodies, to methods of producing these molecules and methods of using the same.
    Type: Application
    Filed: October 2, 2019
    Publication date: September 3, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Laura CODARRI DEAK, Stefan C. DENGL, Jens FISCHER, Christian KLEIN, Stefan SEEBER, Patrick Alexander Aaron WEBER, Adrian Zwick
  • BISPECIFIC ANTIGEN BINDING MOLECULE FOR A COSTIMULATORY TNF RECEPTOR
    Publication number: 20200277392
    Abstract: The invention relates to novel bispecific antigen binding molecules comprising (a) at least one moiety capable of specific binding to OX40, and (b) at least one moiety capable of specific binding to tenascin C (TnC), and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: September 26, 2019
    Publication date: September 3, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria AMANN, Sandra GRAU-RICHARDS, Christian KLEIN, Mudita PINCHA, Pablo UMAÑA
  • Layout for a touch input surface
    Patent number: 10761569
    Abstract: Techniques for layout for a touch input surface are described. Generally, the described techniques enable a touch input surface and/or combination of touch input surfaces to be characterized as a single logical input surface. Based on different contextual factors, the single logical input surface can be divided into different touch input zones that can each receive touch input to invoke a different respective functionality. In at least some implementations, different haptic effects can be output to correspond to different touch input zones.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: September 1, 2020
    Assignee: Microsoft Technology Licensing LLC
    Inventors: Christian Klein, Roy Henry Berger, Jr.
  • Inference of an intended primary display of a hinged mobile device
    Patent number: 10761799
    Abstract: Techniques for inference of an intended primary display of a hinged mobile device are described. Generally, the techniques described herein improve a user experience when the user interacts with the device, such as to change the posture of the device. For example, the techniques described herein detect physical movement of a first and/or second display portion of the device. In implementations, the physical movement is recognized as a device gesture to indicate which of the display portions is intended to be used as the primary display. Then, a determination is made that the first display portion is intended to be used as the primary display based on the device gesture. Based on the determination, the primary display is initiated via the first display portion.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: September 1, 2020
    Assignee: Microsoft Technology Licensing, LLC
    Inventors: Robert Joseph Disano, Christian Klein, Katherine Blair Huffman
  • ANTIGEN BINDING MOLECULES COMPRISING A TRIMERIC TNF FAMILY LIGAND
    Publication number: 20200270321
    Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) a polypeptide comprising three ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by peptide linkers and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: October 15, 2019
    Publication date: August 27, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Pablo Umana
  • ANTIBODIES AGAINST HUMAN ANGIOPOIETIN 2
    Publication number: 20200262904
    Abstract: The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: September 26, 2019
    Publication date: August 20, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thomas Regula, Werner Scheuer
  • Input adjustment
    Patent number: 10747365
    Abstract: Techniques for input adjustment are described. In one or more implementations, a user perspective of a display surface is estimated, and is used to correlate output that is displayed on the display surface. According to one or more implementations, detected motion of a display surface is used to compensate for an effect of the motion on input to the display surface.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: August 18, 2020
    Assignee: Microsoft Technology Licensing, LLC
    Inventors: Christian Klein, Jan-Kristian Markiewicz
  • COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR
    Publication number: 20200253963
    Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
    Type: Application
    Filed: March 23, 2020
    Publication date: August 13, 2020
    Applicants: GENENTECH, INC., F. HOFFMANN-LA ROCHE AG
    Inventors: Deepak Sampath, Christian Klein, Wayne John Fairbrother
  • BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND ROR1
    Publication number: 20200255521
    Abstract: A bispecific antibody specifically binding to the two targets human CD3? (further named also as “CD3”) and the extracellular domain of human ROR1 (further named also as “ROR1”), characterized in that the bispecific antibody does not internalize in a cell based assay at 37° C. during 2 hrs, using ROR1-positive B-CLL cells and used at an antibody concentration of 1 nM, whereby not internalize means, that the mean fluorescence intensity (MFI), as detected by flow cytometry, of a bispecific antibody upon binding to ROR1-positive primary B-CLL cells measured at time 0 is not reduced for more than 50%, preferably not more than 30% when re-measured after a 2 hr-incubation at 37° C. and which is useful for the treatment of B-cell malignancies like Chronic Lymphocytic Leukemia or B-cell disorders expressing ROR1 and ROR1-positive solid tumors.
    Type: Application
    Filed: January 27, 2020
    Publication date: August 13, 2020
    Inventors: Minh Diem VU, Klaus Strein, Ekkehard Moessner, Ralf Hosse, Oliver Ast, Anne Freimoser-Grundschober, Tanja Fauti, Ramona Murr, Christian Klein, Pablo Umana, Samuel Moser
  • ANTIGEN BINDING MOLECULES COMPRISING A TNF FAMILY LIGAND TRIMER
    Publication number: 20200247904
    Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.
    Type: Application
    Filed: July 25, 2019
    Publication date: August 6, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Joerg Thomas Regula, Pablo Umana
  • Dynamic device interaction adaptation based on user engagement
    Patent number: 10732826
    Abstract: The techniques disclosed herein enable dynamic device interaction adaptation based on user engagement. In general, a computer can leverage sensors to determine a user's level of engagement with one or more devices. As the user transitions his or her attention to different devices, the computer can utilize different interaction models to assist the user in interacting with each device that meets a threshold level of engagement with the user. Individual interaction models can configure the computer to direct input gestures received by the computing device to a selected device, and adapt the computer's input modality to provide user interface controls that are optimized for the selected device. When a user is interacting with two or more devices, automatic transitions between different interaction models can help improve the user's interaction with each device.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: August 4, 2020
    Assignee: Microsoft Technology Licensing, LLC
    Inventors: Christian Klein, Andrew Stuart Glass
  • Facilitating interaction with a computing device based on force of touch
    Patent number: 10725647
    Abstract: A technique is described herein that allows a user to control a user interface presentation provided by a computing device based on a force-dependent manner in which the user engages a surface of a force-sensitive input device. This manner of control allows any user to efficiently interact with the computing device, but is particularly beneficial to users who have motor-related and/or vision-related disabilities.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: July 28, 2020
    Assignee: Microsoft Technology Licensing, LLC
    Inventors: Christian Klein, Robert Disano, Robert David Steen
  • BISPECIFIC ANTIGEN BINDING MOLECULE FOR A COSTIMULATORY TNF RECEPTOR
    Publication number: 20200231691
    Abstract: The invention relates to novel bispecific antigen binding molecules comprising (a) at least one moiety capable of specific binding to OX40, and (b) at least one moiety capable of specific binding to epithelial cell adhesion molecule (EpCAM), and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: September 25, 2019
    Publication date: July 23, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Sandra GRAU-RICHARDS, Christian KLEIN, Pablo UMAÑA, Maria AMANN, Laurene POUSSE
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20200231673
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: February 24, 2020
    Publication date: July 23, 2020
    Inventors: Oliver AST, Marina BACAC, Sabine IMHOF-JUNG, Christiane NEUMANN, Christian KLEIN, Stefan KLOSTERMANN, Michael MOLHOJ, Joerg Thomas REGULA, Wolfgang SCHAEFER, Pablo UMANA
  • TUMOR-TARGETED SUPERAGONISTIC CD28 ANTIGEN BINDING MOLECULES
    Publication number: 20200223925
    Abstract: The present invention relates to tumor targeted superagonistic antigen binding molecules capable of multivalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
    Type: Application
    Filed: December 19, 2019
    Publication date: July 16, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stephan GASSER, Guy GEORGES, Thomas HOFER, Christian KLEIN, Jenny Tosca THOM, Pablo UMAÑA